NFE2L2 and cancer: Second, the low frequency of NFE2L2 MUs (1.9–3.6% in pan-cancers) might restrict the therapeutic use of detecting NFE2L2 MUs and explaining the mechanism of disease progression in NFE2L2 mutated tumors.